MGMT and brain cancer: Serum ctDNA was used to detect methylation status of certain genes (MGMT, RASSF1A, CDKN2b, and CDKN2a) associated with the pathogenesis of CNS cancers in a cohort of 33 brain cancer patients (7 primary or recurrent GBM, 8 astrocytomas, 2 gliosarcoma, 6 meningiomas, and 10 other metastatic CNS cancer).